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Colonization with Candida species is an independent risk factor for invasive candidiasis (IC), but the minimum andmost practi-
cable parameters for prediction of IC have not been optimized. We evaluated Candida colonization in a prospective cohort of
6,015 nonneutropenic, critically ill patients. Throat, perineum, and urine were sampled 72 h post-intensive care unit (ICU) ad-
mission and twice weekly until discharge or death. Specimens were cultured onto chromogenic agar, and a subset underwent
molecular characterization. Sixty-three (86%) patients who developed IC were colonized prior to infection; 61 (97%) tested posi-
tive within the first two time points. The median time from colonization to IC was 7 days (range, 0 to 35). Colonization at any
site was predictive of IC, with the risk of infection highest for urine colonization (relative risk [RR] 2.25) but with the sensitiv-
ity highest (98%) for throat and/or perineum colonization. Colonization of>2 sites and heavy colonization of>1 site were sig-
nificant independent risk factors for IC (RR 2.25 and RR 3.7, respectively), increasing specificity to 71% to 74% but decreas-
ing sensitivity to 48% to 58%.Molecular testing would have prompted a resistance-driven decision to switch from fluconazole
treatment in only 11% of patients infected with C. glabrata, based upon species-level identification alone. Positive predictive
values (PPVs) were low (2% to 4%) and negative predictive values (NPVs) high (99% to 100%) regardless of which parameters
were applied. In the Australian ICU setting, culture of throat and perineumwithin the first two time points after ICU admission
captures 84% (61/73 patients) of subsequent IC cases. These optimized parameters, in combination with clinical risk factors,
should strengthen development of a setting-specific risk-predictive model for IC.
Invasive candidiasis (IC), particularly, candidemia, is a signifi-cant cause of mortality in critically ill patients, accounting for
almost a third of nosocomial infections in intensive care units
(ICUs) (1, 2). Early antifungal therapy reduces IC-relatedmortal-
ity and approximately halves the incidence of IC (3–8). Untar-
geted prophylactic antifungal use, however, is expensive, has the
potential to cause adverse drug reactions, andmay select for resis-
tant fungal species (9).
Clinical risk prediction rules that identify the high-risk patients
most likely to benefit from prophylaxis have been developed (10–
16), but those studies have used different sets of predictors, in-
cluding (a) clinical risk factors only and (b) clinical risk factors in
combination with colonization indices (CIs). Those rules have
been applied in various settings and have included assessment at dif-
ferent times postadmission to the ICU and different types of ICU
(surgical ICUs only or mixed medical/surgical ICUs—defined as
units that house both medical and surgical populations). These dif-
ferencesmayexplainwhypredictivemodels andalgorithmshaveper-
formed poorly outside their derivative populations (17).
Since IC is preceded by colonization of mucosal surfaces with
the infecting strain (14, 18–20) and since colonization is an inde-
pendent risk factor for IC (14, 19, 21, 22), it is logical that it should
be incorporated into predictive models (15, 16). Using data from
mixed medical/surgical ICUs in Australia, we demonstrated that
the post hoc addition of colonization parameters to two published
clinical risk factor-only predictive models improved their perfor-
mance characteristics (17).
Although several studies examining colonization as a risk fac-
tor for IC have been published, the methodology has not been
standardized and most were confined to surgical ICUs (14, 23–
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25). Interstudy differences existed with respect to sites of sam-
pling, use of convenience and/or specified sample sites, timing of
first samples and frequency of sampling, quantification of coloni-
zation density, and culture media and methods used for species
identification. Furthermore, nucleic acid-basedmethods of fungal
identification were not included.
A systematic evaluation of Candida colonization in a prospec-
tive multicenter cohort study of Australian ICU patients was con-
ducted between June 2007 and January 2012. The overall project
aimed to develop and validate a clinical culture and colonization-
based risk-predictive model suitable for use in mixed Australian
medical and surgical ICUs. In this study, we determined the utility
of culture on CHROMagar for semiquantitative estimates ofCan-
dida colonization (with parallel molecular testing performed on a
subset of patients), the optimal timing of sample collection, and the
minimum number of sites to be sampled. Our overall aim was to
develop a protocol to optimize detection of colonization status for
inclusion into risk-predictive models of IC in critically ill patients.
MATERIALS AND METHODS
Study design.A total of 6,015 nonneutropenic critically ill patients admit-
ted consecutively to mixed medical and surgical ICUs in seven Australian
hospitals (Westmead, Sydney [n  1,163]; Princess Alexandra, Brisbane
[n  1,231]; Royal Brisbane Women’s and Children’s, Brisbane [n 
896]; St Vincent’sHospital, Sydney [n 611]; RoyalMelbourneHospital,
Melbourne [n  1,227]; Concord Hospital, Sydney [n  371]; and Ne-
pean Hospital, Sydney [n 516]) for at least 72 h were studied prospec-
tively from 15 June 2007 to 1 January 2012. Patients with neutropenia
(absolute neutrophil count 0.5 109/liter) within the first 72 h of ICU
admission were excluded. Approval for the study was obtained from each
respective Human Research Ethics Committee.
Surveillance specimen collection.Published literature (23) and a pre-
liminary study at theWestmeadHospital site suggested that the throat, the
perineum (rather than the groin or rectum), and urine were the most
accessible, feasible, and highest-yield sites for the assessment of Candida
colonization. Sampling techniqueswere standardized across sites. In brief,
standard sterile red-top culturette swabs containing liquid Amies media
(Copan, Murrieta, CA, USA) were used to sample the oropharynx and
perineum (just anterior to the anus), and catheter (or midstream) urine
specimens were obtained. Specimens were obtained independently of any
clinically indicated samples. Preliminary experiments (performedprior to
the commencement of this study) showed that sampling the throat and
perineum with dry swabs followed by immersion in 2 ml nutrient broth
containing 10% glycerol at the bedside was a suitable but less practical
alternative (data not shown). Eswabs (Copan Diagnostics and Becton,
Dickinson andCo., Franklin Lakes,NJ), which allow automated specimen
processing and improvedmicrobial transport and recovery (26, 27), were
not evaluated in this study due to their lack of availability in Australia
during the study period. All three surveillance sites were sampled at 72 h
following ICU admission and twice weekly thereafter until ICU discharge
or death.
Candida surveillance cultures. Swabs of the throat and perineumand
10l of urinewere plated ontoCandida chromogenic agar (CHROMagar,
Paris, France) using a half-plate quantitative urine streaking method.
Plates were incubated at 35°C for 48 h. Candida albicans, Candida tropi-
calis, and Candida krusei were differentiated by color as described by the
manufacturer. All other yeast isolates (nearly all wereCandida glabrata or
Candida parapsilosis as confirmed by multiplex tandem PCR [MT-PCR])
were collectively designated “other Candida spp.” Growth of each mor-
phologically distinct yeast isolate was enumerated semiquantitatively, and
the extent of growthwas classified as none, light (10 colonies),moderate
(10 to 100 colonies), or heavy (100 colonies).
MT-PCR. Swabs of the throat and perineum obtained from the first
205 patients sampled atWestmeadHospital underwentmultiplex tandem
PCR (MT-PCR) analysis in addition to culture. Following culture, the
swabswere placed into 3ml saline solution containing 10%nutrient broth
(Oxoid, Adelaide, South Australia) and stored at 4°C until nucleic acid
was extracted. DNA was isolated from 1 ml of the suspension using a
nucliSENS easyMAG instrument (bioMérieux, Baulkham Hills, New
SouthWales, Australia) according to themanufacturer’s instructions. The
elution volumewas 110l. As previously described (28–30), theMT-PCR
method enabled identification of seven Candida species, including C. al-
bicans, Candida dubliniensis, C. glabrata, Candida guilliermondii, C. kru-
sei, C. parapsilosis complex, and C. tropicalis, as well as Saccharomyces
cerevisiae. An internal positive control (artificial DNA) was included with
each specimen to test for PCR inhibition, and a negative water control was
included in each run to monitor contamination. Urine specimens were
not tested by MT-PCR, as the application of this technology to urine
samples had not yet been validated during the study period.
Definitions. Colonization was defined as the isolation of a Candida
species from at least one surveillance site. Positive samples collected as
part of routine clinicalmanagementwere not included in the analysis. The
colonization index (CI) was defined as the ratio of the number of sites
colonized byCandida spp. to the number of body sites surveyed (14). The
corrected colonization index (CCI) was defined as the ratio of the number
of sites heavily colonized by Candida spp. to the number of body sites
surveyed (14). In this present study, the CCI threshold was reduced from
0.5 (14) to0.3 to accommodate the reduced number of sites surveyed
(three as opposed to five).
Surveillance specimens were collected at 72 h following ICU admis-
sion and twiceweekly thereafter until ICUdischarge or death. Timepoints
1, 2, and 3 were defined as 3 to 4 days, 6 to 8 days, and 9 to 11 days
post-ICU admission, respectively.
IC episodes were defined using modified European Organization for
Research and Treatment of Cancer/Mycoses Study Group (EORTC/
MSG) criteria (12, 17). Patients with candiduria alone were excluded be-
cause this was not considered an invasive infection. IC episodes detected
at least 72 h following ICU admission and within 72 h after ICU discharge
were considered to have been ICU acquired.
Statistical analysis. Surveillance culture results from ICU patients
who did develop IC and from those who did not were compared with
respect to categorical variables that included the anatomical site of colo-
nization, the colonization indices (CI and CCI), the density of coloniza-
tion, the number of colonizing species, and the time of surveillance. The
relative risk of developing IC based on colonization status was calculated
using Fisher’s exact test. A P value of 0.05 was considered significant.
The predictive performance characteristics (including sensitivity, speci-
ficity, positive predictive value [PPV], and negative predictive value
[NPV]) were calculated for each variable studied. MT-PCR and culture
results were compared for the detection of colonization status and the
time to detection of colonization status using Fisher’s exact test. All sta-
tistical calculations were performed using MedCalc (www.medcalc.org).
RESULTS
Patient characteristics. Of the 6,015 patients studied, 73 (1%)
developed IC in the ICU. Fifty-eight (79%) of these had proven
infection, i.e., candidemia (n  43) or noncandidemic IC (n 
15); the remaining 15 (21%) patients were classified as probable
cases (12, 17). Infectionswere caused byC. albicans (n 45, 62%),
C. glabrata (n 8, 11%),C. tropicalis (n 8, 11%),C. parapsilosis
(n 6, 8%),Candida spp. (n 5, 7%), andC. krusei (n 1, 1%).
The median time from ICU admission to the development of
ICU-acquired IC was 11 days (range, 4 to 41; average, 14 days).
Systemic (oral or parenteral) antifungal drugs had been re-
ceived by five (7%) patients prior to ICU admission (days7 to 0)
or at time point 1 (days 3 to 4); by an additional seven (10%)
between days 5 and 7; and by an additional six (8%) between days
8 and 10. Fluconazole therapy was administered in 16 cases of IC
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and caspofungin in 2 cases. Twelve (16%) of 73 patients who de-
veloped IC had received empirical antifungal therapy (none had
received antifungal prophylaxis) prior to diagnosis; 9 (7 with in-
fection due toC. albicans, 1 with infection due toC. lusitaniae, and
1 with infection due to C. tropicalis) (75%) of the 12 had been
treated with fluconazole.
Colonization (culture) versus IC: anatomical site of coloni-
zation. Table 1 summarizes the risk of developing IC by site of colo-
nization over the first three time points. A total of 3,511 (60%), 2,025
(63%), and 1,162 (64%) patients were colonized at time points 1
(days3 to4post-ICUadmission),2 (days6 to8post-ICUadmission),
and 3 (days 9 to 11 post-ICU admission), respectively.
Of the 73 patients who developed IC, Candida colonization
was detected in 63 (86%) prior to infection: 56 (89%) of these at
time point 1, an additional 5 at time point 2, and a further 2 at time
point 3. Patients with detected colonization in the throat,
perineum, or urine at time point 1 were all at increased risk of
developing IC (relative risk [RR]  2.35, P value  0.002, sensi-
tivity 78%),with colonization of the urine being associatedwith
the highest relative risk of IC (RR  2.25) compared with throat
and perineum (RR 2.04 and 1.76, respectively; Table 1). At time
points 2 and 3, patients colonized in the throat or in at least one of
the three sites sampled (CI 0.3) were at increased risk of devel-
oping IC. NPVs were consistently high (99% to 100%; Table 1).
Of the 63 patients in whomCandida colonization was detected
prior to infection, 38 were colonized in at least two sites, most
commonly the throat and perineum (n  32, 84%). Nineteen
(30%) patients with IC were colonized in the throat alone, five
(8%) in the perineum alone, and one (2%) in the urine alone.
The median time from the first positive surveillance specimen
to the first positive clinical culture was 7 days (range, 0 to 35;
average, 9 days).
Ten patients (14%) had negative surveillance cultures prior to
the development of IC. Seven (70%) of the 10 patients had only
one set of surveillance cultures obtained before discharge from the
ICU. The remaining three had two, five, or seven sets of surveillance
cultures obtained; the times from the last surveillance culture to the
development of IC were 2, 15, and 19 days, respectively. All but 1 of
the 10 patients who had negative surveillance cultures prior to devel-
oping IC had undergone surgery just prior to or during ICU admis-
sion. In six instances where the type of surgery was specified, five had
involved penetration of the gastrointestinal tract.
Colonization index (CI), corrected colonization index (CCI),
and invasive candidasis (IC).Of the 58% patients (n 3,511) in
whom Candida colonization was detected at the first time point,
1,671 (48%) had Candida spp. isolated from at least two surveil-
lance sites (CI  0.5; Table 2). Almost half (n  35, 48%) of the
patients who developed IC had aCI of0.5 (RR 2.25, P value
0.0005; Table 2).
The sensitivity, specificity, and risk of developing IC increased
slightly when heavy colonization was taken into account (CCI
0.3; Table 2). At time point 1, 42 (58%) patients who developed IC
were heavily colonized in at least one site (RR  3.7, P value 
0.0001). Specificity increased (74% to 92%) when two sites were
heavily colonized, but this in turn reduced sensitivity from 58% to
21% (Table 2).
Prevalence ofCandida colonization and incidence of IC over
time in the ICU.Detection ofCandida colonization at any site was
maintained at 60% over the first three time points (Fig. 1). Detec-
tion of perineum colonization increased the most over the first
two screens, while the likelihood of Candida colonization in the
urine increased steadily with prolonged ICU stay. Detection of
Candida colonization in the throat was highest at time point 1 and
decreased with time in the ICU. Of the 73 infected patients, 6, 17,
and 15 patients developed IC within time points 1, 2, and 3, re-
TABLE 1 Risk of invasive candidiasis based on screening time point and anatomical site of colonization (derived from culture results only; entire
patient cohort included)
Variablea n RRb P value
95% confidence
interval (low)
95% confidence
interval (high)
Sensitivity
(%)
Specificity
(%)
PPVc
(%)
NPVd
(%)
Time point 1 (n studied 6,015)
Any site colonized (CIe 0.3) 3,511 2.35 0.002 1.35 4.08 78 40 2 99
At least throat colonized 2,927 2.04 0.004 1.25 3.34 68 49 2 99
At least perineum colonized 1,967 1.76 0.0155 1.1 2.77 48 66 2 99
At least urine colonized 630 2.25 0.003 1.32 3.84 23 88 3 99
Time point 2 (n studied 3,244)
Any site colonized (CI 0.3) 2,025 3.69 0.001 1.66 8.17 86 38 2 99
At least throat colonized 1,555 2.97 0.0007 1.58 5.56 74 51 2 99
At least perineum colonized 1,313 1.54 NSf 0.89 2.67 52 59 2 99
At least urine colonized 450 1.81 NS 0.95 3.44 24 85 3 99
Time point 3 (n studied 1,820)
Any site colonized (CI 0.3) 1,162 1.41 0.0001 1.23 1.61 89 37 2 100
At least throat colonized 837 5.04 0.001 1.93 13.21 82 53 3 99
At least perineum colonized 762 2.04 NS 0.96 4.34 61 57 2 99
At least urine colonized 284 NS
a Time point 1, days 3 to 4 post-ICU admission; time point 2, days 6 to 8 post-ICU admission; time point 3, days 9 to 11 post-ICU admission.
b RR, relative risk.
c PPV, positive predictive value.
d NPV, negative predictive value.
e CI, colonization index.
f NS, not significant.
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spectively, leading to cumulative incidences of IC of 8%, 32%, and
52% within the first three time points (Fig. 1).
Distribution of colonizing species. Most patients were colo-
nized withC. albicans (n 2,854, 81%), followed by “other”Can-
dida spp. (n  1,059, 30%), C. tropicalis (n  343, 10%), and C.
krusei (n  123, 4%). The majority (80%) of patients were colo-
nized with a singleCandida species. Mixed cultures generally con-
sisted of two species (n  662), typically C. albicans with C.
glabrata or C. parapsilosis (n 467, 67%).
All 63 colonized patients who developed IC were colonized
with the species that subsequently caused infection. Twenty (32%)
patients were colonized with two or more Candida species; the
dominant colonizing species caused subsequent infection. The re-
maining 43 patients were colonized with one species (33 with C.
albicans, 8 with “other” Candida spp., and 1 each with C. krusei
and C. tropicalis). The number of colonizing species was not asso-
ciated with the development of IC (data not shown).
Comparison of MT-PCR and culture for the detection of
Candida colonization inpatientswithorwithout IC. In addition
to culture, swabs of the throat and perineum from 205 patients
underwent MT-PCR analysis. The median time of IC acquisition
in this patient cohort was 5 days (range, 4 to 19 days) post-ICU
admission. MT-PCR detected Candida DNA in an additional
seven patients (n  173, 84%) compared with culture (n  166,
81%). No significant difference was found between MT-PCR and
culture for detecting colonization status or between the sampling
periods in which colonization was detected (91% and 93% of col-
onized patients were positive by MT-PCR and culture, respec-
tively, at time point 1).
While only C. albicans, C. tropicalis, and C. krusei were distin-
guished with certainty on CHROMagar (based on the manufac-
turer’s protocol), a further five species, including C. dubliniensis,
C. glabrata,C. guilliermondii,C. parapsilosis, and S. cerevisiae, were
identified by MT-PCR. In this cohort, C. albicans was cultured
from 134 (65%) patients whereasC. albicansDNAwas detected in
only 124 (60%) patients; C. dubliniensis DNA was detected in
these 10 discrepant cases. Non-Candida albicans spp. detected by
MT-PCR includedC. dubliniensis (n 27, 13%),C. glabrata (n
29, 14%),C. guilliermondii (n 3, 1%),C. krusei (n 12, 6%),C.
parapsilosis (n 17, 8%), C. tropicalis (n 15, 7%), and S. cerevi-
siae (n 35, 17%).MT-PCR provided species identification in 73
cases where the species of the yeast could not be determined by
CHROMagar.
The turnaround time forMT-PCR (3 h [but, in practice, 8 to 24
h, allowing for specimen transport and incorporation into routine
laboratory workload]) was shorter than the 48 h required to ob-
tain results from culture-based surveillance.
TABLE 2 Performance characteristics determined using a colonization index value of0.5 and a corrected colonization index value of0.3
(derived from culture results only; entire patient cohort included)
Variablea n RRb P value
95% confidence
interval (low)
95% confidence
interval (high)
Sensitivity
(%)
Specificity
(%)
PPVc
(%)
NPVd
(%)
Time point 1 (n studied 6,015)
At least 2 sites colonized (CIe 0.5) 1,671 2.25 0.0005 1.4 3.5 48 71 2 99
All 3 sites colonized 342 2.25 0.016 1.16 4.34 14 94 3 99
At least one site heavy density (CCIf 0.3) 1,549 3.7 0.0001 2.36 5.93 58 74 3 99
At least 2 sites heavy density 448 3.1 0.001 1.77 5.4 21 92 3 99
At least throat heavy density 1,025 3.77 0.0001 2.39 5.94 45 82 3 99
At least perineum heavy density 703 2 0.01 1.15 3.46 22 88 2 99
At least urine heavy density 327 NSg
Time point 2 (n studied 3,244)
At least 2 sites colonized (CI 0.5) 1,056 2.4 0.002 1.38 4.16 54 67 3 99
All 3 sites colonized 238 NS
At least one site heavy density (CCI 0.3) 915 3.24 0.0001 1.86 5.63 56 72 3 99
At least 2 sites heavy density 287 2.9 0.001 1.5 5.6 22 91 4 99
At least throat heavy density 530 3.93 0.0001 2.26 6.81 44 84 4 99
At least perineum heavy density 481 NS
At least urine heavy density 233 NS
Time point 3 (n studied 1,820)
At least 2 sites colonized (CI 0.5) 596 3.12 0.003 1.47 6.62 61 67 3 99
All 3 sites colonized 122 NS
At least one site heavy density (CCI 0.3) 480 2.1 0.05 0.99 4.39 43 74 3 99
At least 2 sites heavy density 143 NS
At least throat heavy density 253 2.83 0.009 1.3 6.2 32 86 4 99
At least perineum heavy density 263 NS
At least urine heavy density 126 NS
a Time point 1, days 3 to 4 post-ICU admission; time point 2, days 6 to 8 post-ICU admission; time point 3, days 9 to 11 post-ICU admission.
b RR, relative risk.
c PPV, positive predictive value.
d NPV, negative predictive value.
e CI, uncorrected colonization index.
f CCI, corrected colonization index.
g NS, not significant.
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DISCUSSION
In this prospective multicenter study, we systematically deter-
mined the most effective and practical protocol to measure colo-
nization status and predict IC in nonneutropenic patients in
mixed medical/surgical Australian ICUs. As expected, coloniza-
tion was detected in most patients (86%) prior to development of
IC. Standardized cultures of the throat and perineum at time
points 1 and 2 captured 97% (61/63) of colonized patients who
developed IC, a median of 7 days prior to the diagnosis of IC
(designated the diagnostic specimen collection date). Notably,
14% of the patients (n  10) had negative surveillance cultures
prior to the diagnosis of IC, similarly to a Spanish study of mixed
medical/surgical ICUs (19). Based on our prior observation (17),
we expect that this subgroup will be captured when clinical pa-
rameters such as recent gastrointestinal surgery are built into der-
ivation of our model.
Prior Candida colonization is a major risk factor for develop-
ing IC; however, the sites surveyed have differed considerably (14,
19, 21, 31–33). Furthermore, proponents of “clinical only” pre-
diction rules have argued for exclusion of colonization data be-
cause the process is resource intensive and adds to laboratory
costs. Our study determined that collection of samples from three
sites alone (throat, perineum, andurine)was practical and feasible
but was not necessary for routine surveillance, since 98% (62/63)
of colonized patients who subsequently developed IC were cap-
tured by throat and perineum surveillance cultures. In contrast to
our findings, others have indicated that the mouth is not a good
site for routine Candida surveillance due to lower positivity rates
(23); the reason for this difference is not clear butmay be linked to
changes in the oropharyngeal niche and differences in oral hy-
giene practices among ICUs.
To optimize the timing of surveillance cultures, we compared
results of cultures at time points 1, 2, and 3 (Tables 1 and 2 and Fig.
1). In a trend similar to those previously reported by others (21,
34), the majority of colonized patients who subsequently devel-
oped IC tested positive on the first screen (n 56, 89%), indicat-
ing that new colonizing strains are acquired in a minority of pa-
tients after 72 h in the ICU (21). Detection of throat colonization
unexpectedly decreased with time in the ICU (Fig. 1). Selective
decontamination of the digestive tract (SDD) was not used in the
present cohort, although changes to the oropharyngeal flora upon
ICU admission are expected, considering variables such as patient
intubation status, nutritional components, and different oral hy-
giene methods. Since 97% (61/63) of colonized patients who de-
veloped IC had positive surveillance in the throat and/or
perineum within the first two time points and since the median
time from ICU admission to IC was 11 days, we suggest that sur-
veillance cultures taken at 72 h and 7 days post-ICU admission are
sufficient for determining Candida colonization status for inclu-
sion into risk-predictive models.
Multifocal colonization (at least two sites, CI 0.5) and heavy
colonization (at least one site, CCI  0.3) were both significant
independent risk factors in our cohort (Table 2), but the decrease
(78% to 58%) in sensitivity when CCI was applied indicates its
FIG 1 Cumulative incidence of IC and percentage of patients colonized at any site or specifically in the throat, the perineum, or urine over the first three time
points.
Lau et al.
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poor utility for predicting IC in our mixed medical/surgical ICU
population. In the original study by Pittet et al. (14), the CCI
resulted in a 100% PPV compared with the 2% to 4% in our study
(Table 2). This large discrepancy is likely because the CCI (in
the Pittet study) was derived from a small cohort of critically ill
surgical patients who were selected as “high risk for IC” based
onmultiple clinical risk factors and because colonization status
was determined through a variable number of “convenience”
samples received in the laboratory at any time prior to the
development of IC (14). This contrasts with populations, such
as ours, that were selected on the basis of ICU length of stay,
resulting in a low PPV and a high NPV. Defined sampling pro-
tocols and the mixed medical/surgical populations in our ICUs
may also have contributed to the considerable difference with
respect to CCI performance.
As in other studies (20, 23), low PPVs were obtained when
Candida colonization parameters were applied as the sole crite-
rion for predicting IC—mainly due to its low incidence (1% to
2%, as in our study). With a median time from ICU admission
to infection of 11 days (range, 4 to 41), initial screening at 72 h
post-ICU admission was necessary to predict the 25% of cases
that would have been missed had we used the 7-day entry point
proposed by others (16, 22). Excellent NPVs were generated for
all Candida colonization parameters investigated, indicating that
patients with negative surveillance cultures are highly unlikely to
develop disease andwould not benefit from early antifungal inter-
vention. An approach to patient care based on these observations
would in turn reduce hospital costs, drug-related toxicities, and
the likelihood of emerging antifungal resistance.
In a trend similar to those observed in European and North
American studies (2, 19, 21, 22, 34), C. albicanswas the dominant
colonizing (81%) and infecting (77%) species. A rising prevalence
of IC due to non-albicans Candida species has been attributed to
azole prophylaxis and empirical treatment (6, 35–38). Others,
however, have reported negligible effects of systemic antifungal
use on colonization status (including that by C. glabrata, specifi-
cally) (24, 25). In the present study, only 12 of the 63 colonized IC
patients had received antifungal therapy (all empirical; 10 flu-
conazole); hence, associations could not be tested.
MT-PCR was evaluated on a subset of patients (n  205).
Overall, results of detection of colonization status were similar
between MT-PCR and culture (81% and 84%, respectively),
although instances of culture misidentification were found
(namely, C. dubliniensis was misidentified as C. albicans by
CHROMagar). Other than providing species identification in
cases where the yeast could not be identified on CHROMagar
(14%C. glabrata and 8%C. parapsilosis),MT-PCRdidnot provide
sufficient additional information to justify faster results and a 5-fold
cost increase. Furthermore, yeast species determinations can now be
performedrapidly and inexpensively fromcultureusing technologies
such as matrix-assisted laser desorption ionization–time of flight
mass spectrometry (MALDI-TOFMS) (thiswasnot available in clin-
ical laboratories in Australia during the study period).
A potential limitation of this study was its multicenter charac-
teristic, which encompassed possible variations in diagnostic and
therapeutic decisionmaking. Australian ICUs, however, are com-
parable with respect to case mix and management approaches,
and a center effect was not demonstrated when data from individ-
ual hospitals were analyzed and compared (data not shown). In
addition, a large sample size was employed tominimize disparities
and improve the generalizability of results. The possibility of sys-
tematic bias was eliminated by the inclusion of patients who were
admitted consecutively into the ICUs.
In conclusion, after performing a large-scale, multicenter, pro-
spective, systemic evaluation of a variety of Candida colonization
parameters, we propose a simplified protocol to optimize detec-
tion of colonization status for inclusion into risk-predictive mod-
els of IC in critically ill patients. This protocol, consisting of throat
and perineum surveillance sampling at 72 h post-ICU admission
and 3 to 4 days later, capturesmost patients likely to develop IC. It
should be noted that colonization might not be detected prior to
infection in a subset of patients who proceed to develop IC (14%
in our cohort), but we expect that these patients will be captured
by incorporation of clinical risk factors along with these coloniza-
tion data into our final risk-predictive model.
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